Justin B. Klee - Mar 16, 2023 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Role: Co-Chief Executive Officer, Director
Signature: /s/ Joshua B. Cohen, as Attorney in Fact
Stock symbol: AMLX
Transactions as of: Mar 16, 2023
Transactions value $: -$3,186,236
Form type: 4
Date filed: 3/20/2023, 08:31 PM
Previous filing: Jan 10, 2023
Next filing: Jan 11, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AMLX	Common Stock	Sale	-$3.07M	-96.6K	-3.34%	$31.84	2.8M	Mar 16, 2023	Direct	F1, F2
transaction	AMLX	Common Stock	Sale	-$112K	-3.45K	-0.12%	$32.48	2.79M	Mar 16, 2023	Direct	F1, F3
transaction	AMLX	Common Stock	Award	$0	+50K	+1.79%	$0.00	2.84M	Mar 16, 2023	Direct	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AMLX	Stock Option (right to buy)	Award	$0	+225K		$0.00	225K	Mar 16, 2023	Common Stock	225K	$32.08	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.32 to $32.31. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.33 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4	The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
F5	1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.